Press "Enter" to skip to content

Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report

  • Danaher Corporation DHR has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc CTLT.
  • According to the sources, the recent moves by the life science firm valued Catalent at a significant premium. 
  • It’s unclear how Catalent will proceed or whether it’s receptive to a takeover offer, Bloomberg reported citing people familiar with the matter.
  • Related: Danaher Says 2022 ‘Another Great Year,’ Delivers Around 10% Core Revenue Growth.
  • Danaher and Catalent deal could be one of the largest transactions this year in a sleepy dealmaking market, with volumes down two-thirds globally, the report added. 
  • “As a matter of company policy, Catalent does not comment on market rumors or speculation,” the report cited a company spokesperson.
  • Also Read: Catalent-Repligen Merger ‘Seems Unlikely,’ This Analyst Says.
  • Last year, Catalent received an FDA write-up for its syringe filling facility in Belgium, “allegedly” the culprit behind supply shortage for Novo Nordisk A/S’s NVO obesity drug Wegovy.
  • Catalent provides delivery technologies and development solutions for drugs, biologics, and consumer health products. The manufacturer has gained distinction during the pandemic, helping to produce COVID-19 vaccines and treatments in partnership with companies including Moderna Inc MRNAJohnson & Johnson JNJ, and AstraZeneca Plc AZN.
  • Price Action: CTLT shares are up 25.74% at $70.48 during the premarket session on the last check Monday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published.